May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Prevention of Diabetic Retinopathy in Spontaneously Diabetic Torii Rats by a Sulfonylurea, Gliclazide, Independent of Blood Glucose Level
Author Affiliations & Notes
  • K. Mori
    Omiya Medical Center, Jichi Medical School, Saitama, Japan
  • A. Kakehashi
    Omiya Medical Center, Jichi Medical School, Saitama, Japan
  • N. Kinoshita
    Omiya Medical Center, Jichi Medical School, Saitama, Japan
  • H. Yamagami
    Omiya Medical Center, Jichi Medical School, Saitama, Japan
  • M. Kawakami
    Omiya Medical Center, Jichi Medical School, Saitama, Japan
  • Y. Kanazawa
    Omiya Medical Center, Jichi Medical School, Saitama, Japan
  • Footnotes
    Commercial Relationships  K. Mori, None; A. Kakehashi, None; N. Kinoshita, None; H. Yamagami, None; M. Kawakami, None; Y. Kanazawa, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 429. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K. Mori, A. Kakehashi, N. Kinoshita, H. Yamagami, M. Kawakami, Y. Kanazawa; Prevention of Diabetic Retinopathy in Spontaneously Diabetic Torii Rats by a Sulfonylurea, Gliclazide, Independent of Blood Glucose Level . Invest. Ophthalmol. Vis. Sci. 2005;46(13):429.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: We reported that gliclazide, a sulfonylurea, improves retinal leukostasis independent of blood glucose level in the streptozotocin–induced early diabetic retinopathy rat model (Diabetologia 2002). In the present study, we evaluated the effects of gliclazide on the development of diabetic retinopathy (DR) in spontaneously diabetic Torii (STD) rats, which develop severe diabetic ocular complications (Int J Experimental Diab Res 2000). Methods: Gliclazide or glibenclamide, sulfonylureas, was mixed with bait and administered orally after diabetes progressed in the SDT rats. The rats were divided into three groups: the 0.2% gliclazide–treated group (n=7; mean age, 58 weeks), the 0.4% gliclazide–treated group (n=4; mean age, 60 weeks), and the 0.0125% glibenclamide–treated group (n=7; mean age, 58 weeks). DR was evaluated in vivo by fluorescein angiomicroscopy. When extensive hyperfluorescence around the optic disc associated with vascular tortuosity was observed, the rat was confirmed to have DR. Results: The fasting blood glucose level at sacrifice was over 600 mg/dl in all rats except for one rat (330 mg/dl). DR was observed by fluorescein angiomicroscopy in 1/7 eyes (14%) in the 0.2% gliclazide–treated group, 0/4 eyes (0%) in the 0.4% gliclazide–treated group, and 4/7 eyes (57%) in the 0.0125% glibenclamide–treated group. Although there was no significant difference in progression of DR among the groups, the 0.2% gliclazide–treated group and the 0.4% gliclazide–treated group (n=11) considered together had less progression of DR (1/11 eyes, 9%) compared with the 0.0125% glibenclamide–treated group (4/7 eyes, 57%) (p=0.047). Conclusions:Treatment with gliclazide decreased the prevalence of DR in SDT rats independent of the blood glucose level. The extrapancreatic action of gliclazide, i.e., antioxidant, anti–retinal leukostasis, and anti–VEGF effects, might have a therapeutic effect on the development of DR.

Keywords: diabetic retinopathy • diabetes • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×